Clinical Trial Update: First Child Enrolled in Phase 2 Study of Roflumilast Cream, 0.05% (Zoryve, Arcutis) for Infants With AD
The first child has been enrolled in a Phase 2 open-label study evaluating the safety and tolerability of investigational roflumilast cream 0.05% (Zoryve, Arcutis) in infants aged 3 months to less than 24 months with atopic dermatitis (AD).